Blood Res.  2019 Dec;54(4):288-290. 10.5045/br.2019.54.4.288.

Long-term response in refractory AML following azacitidine-failed MDS by salvage decitabine-bridged allogenic transplantation

• Niscola P
• Grazia CD
• Mazzone C
• Tolu B
• de Fabritiis P
• Angelucci

• KMID: 2466597
• DOI: http://doi.org/10.5045/br.2019.54.4.288

Abstract

No abstract available.

MeSH Terms

Azacitidine
Decitabine
Leukemia, Myeloid, Acute
Salvage Therapy
Myelodysplastic Syndromes
Azacitidine
Decitabine

Reference

1. Platzbecker U. Treatment of MDS. Blood. 2019; 133:1096–1107.

2. Santini V, Prebet T, Fenaux P, et al. Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations. Leuk Res. 2014; 38:1381–1391.

3. Voso MT, Niscola P, Piciocchi A, et al. Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia. Eur J Haematol. 2016; 96:344–351.

4. Tendas A, Lissia MF, Piccioni D, et al. Obstacles to adherence to azacitidine administration schedule in outpatient myelodysplastic syndrome and related disorders. Support Care Cancer. 2015; 23:303–305.

5. Santini V. How I treat MDS after hypomethylating agent failure. Blood. 2019; 133:521–529.

6. Niscola P, Tendas A, Cupelli L, et al. Dismal outcome of acute myeloid leukemia secondary to myelodysplastic syndrome and chronic myelomonocytic leukemia after azacitidine failure in a daily-life setting. Acta Haematol. 2015; 133:64–66.

7. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89:2079–2088.

8. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003; 21:4642–4649.

9. Niscola P, Neri B, Catalano G, et al. Decitabine as salvage therapy for primary induction failure of acute myeloid leukemia. Acta Oncol. 2017; 56:1120–1121.

10. Abruzzese E, Trawinska MM, Neri B, et al. Successful decitabine treatment in unfit, elderly patients with acute myeloid leukemia following chronic myeloproliferative neoplasm. Acta Haematol. 2018; 140:231–233.

11. Varaldo R, Raiola AM, Di Grazia C, et al. Haploidentical bone marrow transplantation in patients with advanced myelodysplastic syndrome. Am J Hematol. 2017; 92:E117–E119.

12. Duong VH, Bhatnagar B, Zandberg DP, et al. Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine. Leuk Lymphoma. 2015; 56:1718–1722.